David A. Siegel Century Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 51,000 shares of IPSC stock, worth $39,270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,000Holding current value
$39,270% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding IPSC
# of Institutions
72Shares Held
37.4MCall Options Held
8.7KPut Options Held
10.2K-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$4.17 Million1.48% of portfolio
-
Casdin Capital, LLC New York, NY5.19MShares$4 Million0.45% of portfolio
-
Vr Adviser, LLC New York, NY3.96MShares$3.05 Million0.66% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$2.23 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.38MShares$1.83 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $45.3M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...